Approval · Notice of Compliance 9074 · 2007
AVANDIA: Notice of Compliance 9074
Issued October 5, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9074
- Date
- October 5, 2007
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the dosage and administration section of the product monograph: use in combination with a sulfonylurea should not exceed 4 mg daily
- Therapeutic class
- Antidiabetic agent / insulin resistance reducing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVANDIA | Not yet assigned | — |
Medicinal ingredients
- ROSIGLITAZONE MALEATE 1 MG per TAB
- ROSIGLITAZONE MALEATE 2 MG per TAB
- ROSIGLITAZONE MALEATE 4 MG per TAB
- ROSIGLITAZONE MALEATE 8 MG per TAB